Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
Endocrinology Unit, Department of Clinical & Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Crit Rev Oncol Hematol. 2022 Jan;169:103572. doi: 10.1016/j.critrevonc.2021.103572. Epub 2021 Dec 22.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of malignancies derived from neuroendocrine cells that can occur anywhere along the gastrointestinal tract. GEP-NETs incidence has been steadily increasing over the past decades, in parallel with the increasing incidence of the metabolic syndrome (MetS). It is not yet fully known whether the MetS components (such as obesity, dyslipidemia and type 2 diabetes) could be involved in the etiology of GEP-NETs or could influence their outcomes. In this review, a panel of experts of the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Endocrinology (SIE), and Italian Society of Pharmacology (SIF) provides a critical view of the experimental and clinical evidence about the association of GEP-NETs risk, outcomes, and therapies with the metabolic disorders typical of MetS. The potential therapeutic strategies for an optimal management of patients with both GEP-NETs and MetS are also discussed.
胃肠胰神经内分泌肿瘤（GEP-NETs）是一组源自神经内分泌细胞的异质性恶性肿瘤，可发生在胃肠道的任何部位。在过去几十年中，GEP-NETs 的发病率一直在稳步上升，与代谢综合征（MetS）的发病率上升呈平行关系。目前尚不完全清楚代谢综合征的组成部分（如肥胖、血脂异常和 2 型糖尿病）是否可能参与 GEP-NETs 的病因，或者是否会影响它们的结果。在这篇综述中，意大利肿瘤医学协会（AIOM）、意大利医学糖尿病学会（AMD）、意大利内分泌学会（SIE）和意大利药理学学会（SIF）的一组专家对 GEP-NETs 风险、结果和治疗与代谢综合征典型代谢紊乱之间的关联的实验和临床证据进行了批判性评估。还讨论了用于最佳管理同时患有 GEP-NETs 和 MetS 的患者的潜在治疗策略。
